Mechanisms of resistance to HER family targeting antibodies

Experimental Cell Research

Volumn 316, Issue 7, 2010, Pages 1083-1100

  Kruser, Tim J ^a   Wheeler, Deric L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antibody; EGFR; HER family; HER2; Resistance

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; IMC C 225; IRINOTECAN; LAPATINIB; MONOCLONAL ANTIBODY; PANITUMUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIMERIZATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; NONHUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

EID: 77950628416     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.01.009     Document Type: Review

References (178)

1. Weinstein I.B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000, 21:857-864.
2. Sharma S.V., Fischbach M.A., Haber D.A., Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 2006, 12:4392s-4395s..
3. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2:127-137.
4. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
5. Klapper L.N., Glathe S., Vaisman N., Hynes N.E., Andrews G.C., Sela M., Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4995-5000.
6. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8132-8136.
7. Wallasch C., Weiss F.U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 1995, 14:4267-4275.
8. Marmor M.D., Skaria K.B., Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:903-913.
9. Marti U., Burwen S.J., Wells A., Barker M.E., Huling S., Feren A.M., Jones A.L. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991, 13:15-20.
10. Cao H., Lei Z.M., Bian L., Rao C.V. Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology 1995, 136:3163-3172.
11. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell. Biol. 2001, 3:802-808.
12. Lo H.W., Hsu S.C., Hung M.C. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res. Treat. 2006, 95:211-218.
13. Lo H.W., Hung M.C. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br. J. Cancer 2006, 94:184-188.
14. Lo H.W., Xia W., Wei Y., Ali-Seyed M., Huang S.F., Hung M.C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005, 65:338-348.
15. Psyrri A., Yu Z., Weinberger P.M., Sasaki C., Haffty B., Camp R., Rimm D., Burtness B.A. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin. Cancer Res. 2005, 11:5856-5862.
16. Xia W., Wei Y., Du Y., Liu J., Chang B., Yu Y.L., Huo L.F., Miller S., Hung M.C. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol. Carcinog. 2009, 48:610-617.
17. Hanada N., Lo H.W., Day C.P., Pan Y., Nakajima Y., Hung M.C. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinog. 2006, 45:10-17.
18. Lo H.W., Hsu S.C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J.Y., Hung M.C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005, 7:575-589.
19. Hung L.Y., Tseng J.T., Lee Y.C., Xia W., Wang Y.N., Wu M.L., Chuang Y.H., Lai C.H., Chang W.C. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res. 2008, 36:4337-4351.
20. Hsu S.C., Hung M.C. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J. Biol. Chem. 2007, 282:10432-10440.
21. Lo H.W., Ali-Seyed M., Wu Y., Bartholomeusz G., Hsu S.C., Hung M.C. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J. Cell. Biochem. 2006, 98:1570-1583.
22. Liao H.J., Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol. Biol. Cell 2007, 18:1064-1072.
23. Psyrri A., Egleston B., Weinberger P., Yu Z., Kowalski D., Sasaki C., Haffty B., Rimm D., Burtness B. Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1486-1492.
24. Dittmann K., Mayer C., Kehlbach R., Rodemann H.P. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol. Cancer 2008, 7:69.
25. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1:1311-1318.
26. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 2002, 20:1S-13S.
27. Van Cutsem E., Kohne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pinter T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
28. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., Vega-Villegas M.E., Eng C., Steinhauer E.U., Prausova J., Lenz H.J., Borg C., Middleton G., Kroning H., Luppi G., Kisker O., Zubel A., Langer C., Kopit J., Burris H.A. 3rd, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:2311-2319.
29. Saltz L.B., Lenz H.J., Kindler H.L., Hochster H.S., Wadler S., Hoff P.M., Kemeny N.E., Hollywood E.M., Gonen M., Quinones M., Morse M., Chen H.X. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 2007, 25:4557-4561.
30. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., Berry S.R., Krahn M., Price T., Simes R.J., Tebbutt N.C., van Hazel G., Wierzbicki R., Langer C., Moore M.J. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357:2040-2048.
31. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
32. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., Baselga J., Youssoufian H., Amellal N., Rowinsky E.K., Ang K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354:567-578.
33. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359:1116-1127.
34. Burtness B., Goldwasser M.A., Flood W., Mattar B., Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005, 23:8646-8654.
35. Hecht J.R., Mitchell E., Chidiac T., Scroggin C., Hagenstad C., Spigel D., Marshall J., Cohn A., McCollum D., Stella P., Deeter R., Shahin S., Amado R.G. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:672-680.
36. Giusti R.M., Shastri K., Pilaro A.M., Fuchs C., Cordoba-Rodriguez R., Koti K., Rothmann M., Men A.Y., Zhao H., Hughes M., Keegan P., Weiss K.D., Pazdur R. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin. Cancer Res. 2008, 14:1296-1302.
37. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J.L., Van Laethem J.L., Maurel J., Richardson G., Wolf M., Amado R.G., Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007, 25:1658-1664.
38. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23:1803-1810.
39. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Cote J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
40. Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., Mirtsching B., Cohn A.L., Pippas A.W., Azarnia N., Tsuchihashi Z., Mauro D.J., Rowinsky E.K. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 2006, 24:4914-4921.
41. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6:279-286.
42. Sartore-Bianchi A., Moroni M., Veronese S., Carnaghi C., Bajetta E., Luppi G., Sobrero A., Barone C., Cascinu S., Colucci G., Cortesi E., Nichelatti M., Gambacorta M., Siena S. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 2007, 25:3238-3245.
43. Hirsch F.R., Herbst R.S., Olsen C., Chansky K., Crowley J., Kelly K., Franklin W.A., Bunn P.A., Varella-Garcia M., Gandara D.R. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J. Clin. Oncol. 2008, 26:3351-3357.
44. Freier K., Flechtenmacher C., Walch A., Ohl S., Devens F., Burke B., Hassfeld S., Lichter P., Joos S., Hofele C. Copy number gains on 22q13 in adenoid cystic carcinoma of the salivary gland revealed by comparative genomic hybridization and tissue microarray analysis. Cancer Genet. Cytogenet. 2005, 159:89-95.
45. Koynova D.K., Tsenova V.S., Toncheva D.I. Tissue microarray analysis of C-MYC oncogene copy number changes in larynx carcinoma. ORL. J. Otorhinolaryngol. Relat. Spec. 2005, 67:92-95.
46. Mrhalova M., Plzak J., Betka J., Kodet R. Epidermal growth factor receptor-its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005, 52:338-343.
47. Hanawa M., Suzuki S., Dobashi Y., Yamane T., Kono K., Enomoto N., Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 2006, 118:1173-1180.
48. Chung C.H., Ely K., McGavran L., Varella-Garcia M., Parker J., Parker N., Jarrett C., Carter J., Murphy B.A., Netterville J., Burkey B.B., Sinard R., Cmelak A., Levy S., Yarbrough W.G., Slebos R.J., Hirsch F.R. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 2006, 24:4170-4176.
49. Temam S., Kawaguchi H., El-Naggar A.K., Jelinek J., Tang H., Liu D.D., Lang W., Issa J.P., Lee J.J., Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol. 2007, 25:2164-2170.
50. Chiang W.F., Liu S.Y., Yen C.Y., Lin C.N., Chen Y.C., Lin S.C., Chang K.W. Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas. Oral. Oncol. 2008, 44:270-276.
51. Ch'ng S., Low I., Ng D., Brasch H., Sullivan M., Davis P., Tan S.T. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum. Pathol. 2008, 39:344-349.
52. Sheu J.J., Hua C.H., Wan L., Lin Y.J., Lai M.T., Tseng H.C., Jinawath N., Tsai M.H., Chang N.W., Lin C.F., Lin C.C., Hsieh L.J., Wang T.L., Shih Ie M., Tsai F.J. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 2009, 69:2568-2576.
53. Schernhammer E.S., Giovannuccci E., Fuchs C.S., Ogino S. A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2895-2898.
54. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., Bastit L., Killian A., Sesboue R., Tuech J.J., Queuniet A.M., Paillot B., Sabourin J.C., Michot F., Michel P., Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 2007, 96:1166-1169.
55. De Roock W., Piessevaux H., De Schutter J., Janssens M., De Hertogh G., Personeni N., Biesmans B., Van Laethem J.L., Peeters M., Humblet Y., Van Cutsem E., Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 2008, 19:508-515.
56. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
57. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
58. Bokemeyer C., Bondarenko I.I., Hartmann J., De Braud F., Volovat C., Nippgen L., Stroh C., Celik I. K. P., KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience 2008, May 20: 4000.
59. Punt C.J., Tol J., Rodenburg C.J., Cats A., Creemers G.M., Schrama J.G., Erdkamp F.L., Vos A., Mol L., Antonini N.F. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) May 20 2008.
60. Van Cutsem E., Lang I., D'haens G., Moiseyenko V., Zaluski J., Folprecht G., Tejpar S., Kisker O., Stroh C., Rougier P. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience May 20. 2008, 2.
61. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., McAllister P.K., Morton R.F., Schilsky R.L. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27:2091-2096.
62. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., Tan B.R., Krishnamurthi S.S., Burris H.A., Poplin E.A., Hidalgo M., Baselga J., Clark E.A., Mauro D.J. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25:3230-3237.
63. Forbes S., Bharma G., Bamford S. The catalogue of somatic mutations in cancer (COSMIC) 2008.
64. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba II, Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., Gazdar A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97:339-346.
65. Le Calvez F., Mukeria A., Hunt J.D., Kelm O., Hung R.J., Taniere P., Brennan P., Boffetta P., Zaridze D.G., Hainaut P. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005, 65:5076-5083.
66. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009, 69:1851-1857.
67. Graziano F., Ruzzo A., Loupakis F., Canestrari E., Santini D., Catalano V., Bisonni R., Torresi U., Floriani I., Schiavon G., Andreoni F., Maltese P., Rulli E., Humar B., Falcone A., Giustini L., Tonini G., Fontana A., Masi G., Magnani M. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 2008, 26:1427-1434.
68. Goncalves A., Esteyries S., Taylor-Smedra B., Lagarde A., Ayadi M., Monges G., Bertucci F., Esterni B., Delpero J.R., Turrini O., Lelong B., Viens P., Borg J.P., Birnbaum D., Olschwang S., Viret F. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 2008, 8:169.
69. Kurai J., Chikumi H., Hashimoto K., Yamaguchi K., Yamasaki A., Sako T., Touge H., Makino H., Takata M., Miyata M., Nakamoto M., Burioka N., Shimizu E. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 2007, 13:1552-1561.
70. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
71. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:13306-13311.
72. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
73. Mukohara T., Engelman J.A., Hanna N.H., Yeap B.Y., Kobayashi S., Lindeman N., Halmos B., Pearlberg J., Tsuchihashi Z., Cantley L.C., Tenen D.G., Johnson B.E., Janne P.A. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 2005, 97:1185-1194.
74. Viloria-Petit A., Crombet T., Jothy S., Hicklin D., Bohlen P., Schlaeppi J.M., Rak J., Kerbel R.S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61:5090-5101.
75. Ciardiello F., Bianco R., Caputo R., Caputo R., Damiano V., Troiani T., Melisi D., De Vita F., De Placido S., Bianco A.R., Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 2004, 10:784-793.
76. Wheeler D.L., Huang S., Kruser T.J., Nechrebecki M.M., Armstrong E.A., Benavente S., Gondi V., Hsu K.T., Harari P.M. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
77. Sok J.C., Coppelli F.M., Thomas S.M., Lango M.N., Xi S., Hunt J.L., Freilino M.L., Graner M.W., Wikstrand C.J., Bigner D.D., Gooding W.E., Furnari F.B., Grandis J.R. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 2006, 12:5064-5073.
78. Lu Y., Li X., Liang K., Luwor R., Siddik Z.H., Mills G.B., Mendelsohn J., Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007, 67:8240-8247.
79. Wheeler D.L., Iida M., Kruser T.J., Nechrebecki M.M., Dunn E.F., Armstrong E.A., Huang S., Harari P.M. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol. Ther. 2009, 8:696-703.
80. Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C., McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C. Tyrosine phosphorylation controls PCNA function through protein stability. Nat. Cell. Biol. 2006, 8:1359-1368.
81. Li C., Iida M., Dunn E.F., Ghia A.J., Wheeler D.L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009, 28:3801-3813.
82. King C.R., Kraus M.H., Aaronson S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229:974-976.
83. Shih C., Padhy L.C., Murray M., Weinberg R.A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981, 290:261-264.
84. Sliwkowski M.X. Ready to partner. Nat. Struct. Biol. 2003, 10:158-159.
85. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997, 16:1647-1655.
86. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 1996, 16:5276-5287.
87. Menard S., Casalini P., Campiglio M., Pupa S.M., Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell. Mol. Life Sci. 2004, 61:2965-2978.
88. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
89. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
90. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
91. Berger M.S., Locher G.W., Saurer S., Gullick W.J., Waterfield M.D., Groner B., Hynes N.E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988, 48:1238-1243.
92. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182.
93. Hudziak R.M., Schlessinger J., Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7159-7163.
94. Yano T., Doi T., Ohtsu A., Boku N., Hashizume K., Nakanishi M., Ochiai A. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol. Rep. 2006, 15:65-71.
95. Mimura K., Kono K., Hanawa M., Mitsui F., Sugai H., Miyagawa N., Ooi A., Fujii H. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br. J. Cancer 2005, 92:1253-1260.
96. Khan A.J., King B.L., Smith B.D., Smith G.L., DiGiovanna M.P., Carter D., Haffty B.G. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 2002, 8:540-548.
97. Morrison C., Zanagnolo V., Ramirez N., Cohn D.E., Kelbick N., Copeland L., Maxwell G.L., Fowler J.M. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J. Clin. Oncol. 2006, 24:2376-2385.
98. Hirsch F.R., Varella-Garcia M., Franklin W.A., Veve R., Chen L., Helfrich B., Zeng C., Baron A., Bunn P.A. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer 2002, 86:1449-1456.
99. Latif Z., Watters A.D., Dunn I., Grigor K.M., Underwood M.A., Bartlett J.M. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br. J. Cancer 2003, 89:1305-1309.
100. Paik S., Hazan R., Fisher E.R., Sass R.E., Fisher B., Redmond C., Schlessinger J., Lippman M.E., King C.R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol. 1990, 8:103-112.
101. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 1989, 9:1165-1172.
102. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4285-4289.
103. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
104. Gasparini G., Gion M., Mariani L., Papaldo P., Crivellari D., Filippelli G., Morabito A., Silingardi V., Torino F., Spada A., Zancan M., De Sio L., Caputo A., Cognetti F., Lambiase A., Amadori D., Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res. Treat. 2007, 101:355-365.
105. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., Utriainen T., Kokko R., Hemminki A., Tarkkanen M., Turpeenniemi-Hujanen T., Jyrkkio S., Flander M., Helle L., Ingalsuo S., Johansson K., Jaaskelainen A.S., Pajunen M., Rauhala M., Kaleva-Kerola J., Salminen T., Leinonen M., Elomaa I., Isola J. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006, 354:809-820.
106. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
107. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
108. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Chan S., Grimes D., Anton A., Lluch A., Kennedy J., O'Byrne K., Conte P., Green M., Ward C., Mayne K., Extra J.M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005, 23:4265-4274.
109. Buzdar A.U., Ibrahim N.K., Francis D., Booser D.J., Thomas E.S., Theriault R.L., Pusztai L., Green M.C., Arun B.K., Giordano S.H., Cristofanilli M., Frye D.K., Smith T.L., Hunt K.K., Singletary S.E., Sahin A.A., Ewer M.S., Buchholz T.A., Berry D., Hortobagyi G.N. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 2005, 23:3676-3685.
110. Lane H.A., Motoyama A.B., Beuvink I., Hynes N.E. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann. Oncol. 2001, 12(Suppl 1):S21-22.
111. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., Hynes N.E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 2000, 20:3210-3223.
112. Cuello M., Ettenberg S.A., Clark A.S., Keane M.M., Posner R.H., Nau M.M., Dennis P.A., Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61:4892-4900.
113. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., Castiglioni F., Villani L., Magalotti C., Gibelli N., Oliviero B., Ballardini B., Da Prada G., Zambelli A., Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 2004, 10:5650-5655.
114. Austin C.D., De Maziere A.M., Pisacane P.I., van Dijk S.M., Eigenbrot C., Sliwkowski M.X., Klumperman J., Scheller R.H. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 2004, 15:5268-5282.
115. Cooley S., Burns L.J., Repka T., Miller J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol. 1999, 27:1533-1541.
116. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
117. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., Shepard H.M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 1993, 37:255-263.
118. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61:4744-4749.
119. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., Cristofanilli M., Arun B., Esmaeli B., Fritsche H.A., Sneige N., Smith T.L., Hortobagyi G.N., Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:1800-1808.
120. Kostler W.J., Schwab B., Singer C.F., Neumann R., Rucklinger E., Brodowicz T., Tomek S., Niedermayr M., Hejna M., Steger G.G., Krainer M., Wiltschke C., Zielinski C.C. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 10:1618-1624.
121. Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17:2235-2249.
122. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
123. Pietras R.J., Poen J.C., Gallardo D., Wongvipat P.N., Lee H.J., Slamon D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999, 59:1347-1355.
124. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
125. Klos K.S., Zhou X., Lee S., Zhang L., Yang W., Nagata Y., Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003, 98:1377-1385.
126. Wen X.F., Yang G., Mao W., Thornton A., Liu J., Bast R.C., Le X.F. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006, 25:6986-6996.
127. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L., Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14:737-744.
128. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17:2639-2648.
129. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
130. Seidman A.D., Fornier M.N., Esteva F.J., Tan L., Kaptain S., Bach A., Panageas K.S., Arroyo C., Valero V., Currie V., Gilewski T., Theodoulou M., Moynahan M.E., Moasser M., Sklarin N., Dickler M., D'Andrea G., Cristofanilli M., Rivera E., Hortobagyi G.N., Norton L., Hudis C.A. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 2001, 19:2587-2595.
131. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
132. Depowski P.L., Rosenthal S.I., Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 2001, 14:672-676.
133. Valabrega G., Montemurro F., Sarotto I., Petrelli A., Rubini P., Tacchetti C., Aglietta M., Comoglio P.M., Giordano S. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 2005, 24:3002-3010.
134. DiGiovanna M.P., Stern D.F., Edgerton S.M., Whalen S.G., Moore D., Thor A.D. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol. 2005, 23:1152-1160.
135. Wang S.E., Xiang B., Guix M., Olivares M.G., Parker J., Chung C.H., Pandiella A., Arteaga C.L. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol. 2008, 28:5605-5620.
136. Zabrecky J.R., Lam T., McKenzie S.J., Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem. 1991, 266:1716-1720.
137. Ali S.M., Carney W.P., Esteva F.J., Fornier M., Harris L., Kostler W.J., Lotz J.P., Luftner D., Pichon M.F., Lipton A. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008, 113:1294-1301.
138. Price-Schiavi S.A., Jepson S., Li P., Arango M., Rudland P.S., Yee L., Carraway K.L. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int. J. Cancer 2002, 99:783-791.
139. Nagy P., Friedlander E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., Jovin T.M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65:473-482.
140. Anido J., Scaltriti M., Bech Serra J.J., Santiago Josefat B., Todo F.R., Baselga J., Arribas J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 2006, 25:3234-3244.
141. Dokmanovic M., Hirsch D.S., Shen Y., Wu W.J. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol. Cancer Ther. 2009, 8:1557-1569.
142. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
143. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., Scher H.I., Sliwkowski M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
144. Diermeier S., Horvath G., Knuechel-Clarke R., Hofstaedter F., Szollosi J., Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp. Cell. Res. 2005, 304:604-619.
145. Motoyama A.B., Hynes N.E., Lane H.A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002, 62:3151-3158.
146. Anastasi S., Sala G., Huiping C., Caprini E., Russo G., Iacovelli S., Lucini F., Ingvarsson S., Segatto O. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 2005, 24:4540-4548.
147. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., Arteaga C.L. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 2007, 13:4909-4919.
148. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
149. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001, 93:1852-1857.
150. Lu Y., Zi X., Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 2004, 108:334-341.
151. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65:11118-11128.
152. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68:1471-1477.
153. Nahta R., Takahashi T., Ueno N.T., Hung M.C., Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004, 64:3981-3986.
154. du Manoir J.M., Francia G., Man S., Mossoba M., Medin J.A., Viloria-Petit A., Hicklin D.J., Emmenegger U., Kerbel R.S. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin. Cancer Res. 2006, 12:904-916.
155. Moulder S.L., Yakes F.M., Muthuswamy S.K., Bianco R., Simpson J.F., Arteaga C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001, 61:8887-8895.
156. Normanno N., Campiglio M., De L.A., Somenzi G., Maiello M., Ciardiello F., Gianni L., Salomon D.S., Menard S. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 2002, 13:65-72.
157. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004, 64:5355-5362.
158. Matar P., Rojo F., Cassia R., Moreno-Bueno G., Di Cosimo S., Tabernero J., Guzman M., Rodriguez S., Arribas J., Palacios J., Baselga J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 2004, 10:6487-6501.
159. Nahta R., Hung M.C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64:2343-2346.
160. Erjala K., Sundvall M., Junttila T.T., Zhang N., Savisalo M., Mali P., Kulmala J., Pulkkinen J., Grenman R., Elenius K. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 2006, 12:4103-4111.
161. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S.D., Stein S., Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355:2733-2743.
162. Li C., Iida M., Dunn E.F., Ghia A.J., Wheeler D.L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009.
163. Liao H.J., Carpenter G. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res. 2009, 69:6179-6183.
164. Kim H.P., Han S.W., Kim S.H., Im S.A., Oh D.Y., Bang Y.J., Kim T.Y. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther. 2008, 7:607-615.
165. Ciardiello F., Bianco R., Caputo R., Damiano V., Troiani T., Melisi D., De Vita F., De Placido S., Bianco A.R., Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 2004, 10:784-793.
166. Morelli M.P., Cascone T., Troiani T., Tuccillo C., Bianco R., Normanno N., Romano M., Veneziani B.M., Fontanini G., Eckhardt S.G., De Pacido S., Tortora G., Ciardiello F. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J. Cell. Physiol. 2006, 208:344-353.
167. Camirand A., Lu Y., Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med. Sci. Monit. 2002, 8:BR521-BR526.
168. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science 2007.
169. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., Rinehart C., Seidel B., Yee D., Arteaga C.L., Engelman J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118:2609-2619.
170. Song L., Morris M., Bagui T., Lee F.Y., Jove R., Haura E.B. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006, 66:5542-5548.
171. Wheeler D.L., Iida M., Kruser T.J., Nechrebecki M.M., Dunn E.F., Armstrong E.A., Huang S., Harari P.M. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol. Ther. 2009, 8.
172. Mitra D., Brumlik M.J., Okamgba S.U., Zhu Y., Duplessis T.T., Parvani J.G., Lesko S.M., Brogi E., Jones F.E. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol. Cancer Ther. 2009, 8:2152-2162.
173. Benavente S., Huang S., Armstrong E.A., Chi A., Hsu K.T., Wheeler D.L., Harari P.M. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin. Cancer Res. 2009, 15:1585-1592.
174. Perrone F., Lampis A., Orsenigo M., Di Bartolomeo M., Gevorgyan A., Losa M., Frattini M., Riva C., Andreola S., Bajetta E., Bertario L., Leo E., Pierotti M.A., Pilotti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 2009, 20:84-90.
175. Prenen H., De Schutter J., Jacobs B., De Roock W., Biesmans B., Claes B., Lambrechts D., Van Cutsem E., Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 2009, 15:3184-3188.
176. Mahtani R.L., Macdonald J.S. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist 2008, 13:39-50.
177. Rajput A., Koterba A.P., Kreisberg J.I., Foster J.M., Willson J.K., Brattain M.G. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res. 2007, 67:665-673.
178. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., Zhu X., Humphrey P.A., Friedman H.S., Bigner D.D. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell. Growth Differ. 1995, 6:1251-1259.